Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite BioPharma received a patent allowance from the Japan Patent Office covering the use of Namodenoson for inducing fat loss and treating obesity. This allowance strengthens the company's global intellectual property portfolio for the drug candidate, which already has secured protection in the U.S., Canada, Australia, and Israel.
Key figures
- Drug Name
- Namodenoson
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.